Person:
ÇAKIR, FATMA BETÜL

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
FATMA BETÜL
Last Name
ÇAKIR
Name
Email Address
Birth Date

Filters

2022 - 20247
Reset filters

Settings

Start date: 2020 × Type: article × Subject: Clinical Medicine (MED) ×

Search Results

Now showing 1 - 7 of 7
  • No Thumbnail Available
    PublicationMetadata only
    Cancer-Related Fatigue and Daily Living Activities in Pediatric Cancer Survivors
    (2022-11-01) Tanrıverdi M.; Çakır F. B.; TANRIVERDİ, MÜBERRA; ÇAKIR, FATMA BETÜL
  • No Thumbnail Available
    PublicationMetadata only
  • No Thumbnail Available
    PublicationUnknown
    The Relationship of Prognostic Factors with Regulatory T Cells in Langerhans Cell Histiocytosis
    (2023-12-01) Çoban G.; Coşanay Tekden B.; Güler B.; Çakır F. B.; Toluk Ö.; Gücin Z.; Elagöz Ş.; ÇOBAN, GANİME; COŞANAY TEKDEN, BÜŞRA; GÜLER, BERIL; ÇAKIR, FATMA BETÜL; GÜCİN, ZÜHAL; ELAGÖZ, ŞAHANDE
  • No Thumbnail Available
    PublicationUnknown
    EARTHQUAKE DISASTER AND ITS' ACUTE EFFECT ON PEDIATRIC HEMATOLOGY AND ONCOLOGY.IN TURKIYE; TURKISH PEDIATRIC ONCOLOGY GROUP-TPOG QUESTIONARE STUDY
    (2023-11-01) TAÇYILDIZ N.; İNCESOY ÖZDEMİR S.; Kupeli B.; Cemaloglu M.; Acipayam C.; Oncel K.; Akinel A. N.; Karabel N.; Coskun C.; SEZGİN G.; et al.; ÇAKIR, FATMA BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    KAPOSIFORM HEMANGIOENDOTHELIOMA AND REFRACTORY KASABACH-MERRITT PHENOMENON TREATED WITH SIROLIMUS
    (2023-11-01) EREN T.; ÇAKIR F. B.; ÇAKIR, FATMA BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    Pediatric mediastinal tumors Çocukluk çağı mediasten tümörleri
    (2024-01-01) SOYSAL Ö.; Çakır F. B.; SOYSAL, ÖMER; ÇAKIR, FATMA BETÜL
    Mediastinal tumors are the most common thoracic tumor in the pediatric population. They include a spectrum of tumors, and most are malignant. These lesions can be anatomically and radiologically classified by means of compartments; anterior, middle, and posterior. Symptoms, signs, localization of the tumor, age of the child, and tumor markers are key points of diagnosis. Surgical approaches are typically needed for diagnosis, but sometimes tru-cut needle biopsies may be sufficient. Mediastinoscopy, mediastinotomy, and video-assisted thoracoscopic surgery may be used in the diagnostic workup of mediastinal tumors in children as they are used in adults. Frequently, diagnosis and treatment are both established by means of surgery. Surgery remains the mainstay of treatment of most benign and malignant nonlymphoid tumors. Combined modality of treatment incorporating chemotherapy and radiotherapy is often required in malignant tumors and is associated with high survival rates in these patients.
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
    (2024-01-01) Nayır Büyükşahin H.; EMİRALİOĞLU ORDUKAYA N.; Yalçın E.; Şen V.; Selimoğlu Şen H.; Arslan H.; Başkan A. K.; Çakır F. B.; Koray C. F.; Yılmaz A. İ.; et al.; ÇAKIR, FATMA BETÜL; OGUN, HAMZA; YAZAN, HAKAN; ÇAKIR, ERKAN
    Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the ‘Vertex treatment-Finder\" on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p =.010), lower median height z-scores (−0.87 vs. −0.55, p <.001), lower median body mass index z-scores (−0.65 vs. −0.50, p <.001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0–2] vs. 0 [IQR: 0–7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes.